September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 1 GCP QA for Russia and the Ukraine.

Slides:



Advertisements
Similar presentations
Our Vision:- We; Jupiter Research Services; are a Clinical Research Service provider, providing the core clinical research services like site management,
Advertisements

Tips to a Successful Monitoring Visit
GCP for Investigators Tina Lidén Mascher, Kvalitetsregister, forskning och industrisamarbeten.
Dr. M. Iwasaki 1 Asian Multinational Clinical Trials - Current Status & Future Direction - Dr.Masaru IWASAKI PR Japan Operations Center Aventis Pharma,
By Ulus Salih Akarca Ege University Faculty of Medicine Department of Gastroenterology CLINICAL RESEARCHES ASSOCIATION AUDIT AND FOLLOW-UP IN CLINICAL.
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
Good Clinical Practices Regulatory Guidelines for the Conduct of Clinical research Introduction to Research Pharmacy Services Javier Palacios, R.Ph. Sponsored.
Monitoring and Auditing
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Capturing and Reporting Adverse Events in Clinical Research
Laboratory Personnel Dr/Ehsan Moahmen Rizk.
Contact: For education: Kornelia Hathaway, Education & Training Manager, For.
ABS Health, LLC 12466, E Washington Blvd, Whittier, CA – Phone
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
MAGI's Clinical Trial Agreements, Budgets & Regulatory Conference FDA Inspections of Investigator Sites Paul Below Clinical Research Consultant P. Below.
Good Clinical Practice GCP
Overview of Good Clinical Practices (GCPs)
Healing Hands Clinical Research Services is a clinical Research Service Provider which has broad spectrum of.
Healing Hands Clinical Research Services is a Site Management organization with broad spectrum of activities.
Why companies saying or should say “YES” to India for Studies.
GIQAR Annual Congress 25 – 26 th May Pv QA: Quality Assurance for Pharmacovigilance Allison Jack Manager, R&D Oversight – GCP/PV, Pfizer Ltd BARQA.
Monitoring and Special Considerations for Multi-Center Trials
Q UINTILES INDIA Opportunities and Experiences in conducting Clinical Trials in India Narges Mahaluxmivala MD (Bom), DTM&H (Eng) Quintiles India September.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
Clinical Trials Market in Russia 17 October 2008 ROTOBO - ACTO.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Research Ethics Review Malaysian experince Dato Dr. Zaki Morad. Chairperson MREC Dr. Lim TO. Member MREC MOH Malaysia.
Audits and Inspections in Clinical Research Jobin Kunjumon Vilapurathu.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
SIPLAS RO is a full service contract research organization CRO, offering nanotechnology, biopharmaceutical and medical device companies comprehensive.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
Read the SMALL PRINT of the 1572 The Essential GCP Document.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
Integrating a Federated Healthcare Data Query Platform With Electronic IRB Information Systems Shan He IPHIE 2010.
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
How to Start An Industry Sponsored Clinical Trial
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Briefing on MHRA routine inspection of non-commercial clinical trials
Supervisory Responsibilities of Clinical Investigators
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Principles of Good Clinical Practice (GCP) – What is it all about and who is responsible for adherence? GCP and QA All SIAC Call Mar 14, 2008 Munish Mehra,
Responsibilities of Sponsor, Investigator and Monitor
Nordic Cooperation on Ethical Review Procedures Nordforsk – nordic trial alliance MIKA SCHEININ
Investigator-initiated Research What Are your Responsibilities?
MAINTAINING THE INVESTIGATOR’S SITE FILE
Natalia Nayanova Director of Clinical Operations and General Manager
Administering Informed Consent Issues for Discussion
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Elements of an Organized Regulatory Binder
MAINTAINING THE INVESTIGATOR’S STUDY FILE
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Good clinical practice
PHARMACOVIGILANCE SYSTEM
Presentation transcript:

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 1 GCP QA for Russia and the Ukraine

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 2 Attractive Features Attractive Features FDA Inspections Overview in Russia and Ukraine FDA Inspections Overview in Russia and Ukraine Review of Personal Data from the Audits Review of Personal Data from the Audits Compliance Issues in Russia and Ukraine and Possible Resolutions Compliance Issues in Russia and Ukraine and Possible Resolutions Recommendations Recommendations GCP QA for Russia and the Ukraine

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 3 Comparative Characteristics Area (1000 km 2 ) Inhabitants (Million) Major Cities (more 1.0 Mill) Physicians per 1000 Inhabit. Hospital Beds per 1000 Inhabit. Russia 17, Ukraine USA 9,

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 4 Attractive Features (Russia and the Ukraine) Population: Prevalence of Different Diseases, Including Rare ones Treatment-naïve Patients Low Residential Movements Patients’ Compliance

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 5 Attractive Features (Russia and the Ukraine) Healthcare System Features: Centralized and Vertical Healthcare Well-maintained Patient Databases Large In-patient Facilities Long Hospital Stays

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 6 Example of Enrollment Rate - 1

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 7 Example of Enrollment Rate - 2

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 8 Attractive Features (Russia and the Ukraine) Clinical Investigators: Highly Motivated to Participate in Trials Level of Medical Training and Education Good Cooperation with Monitors Study Coordinators – Qualified Physicians Trust-based Relationships between Patients and Investigators

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 9 Example of Drop-out Rate

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 10 Attractive Features (Russia and the Ukraine) Regulations Compatible with ICH GCP National Ethics Committee Data Quality: There have been Many Reports from Different Sources of the High Quality of Data Obtained in Russia and Ukraine

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 11 Example of Query Rate

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 12 Clinical Trails Performed by Sponsors 2008 – about trials in USA

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 13 FDA Inspections in Russia

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 14 Results of FDA Inspections RussiaUkraine NAI285 VAI212 OAI10 Total507

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 15 FDA Inspections in Russia and the Ukraine Most Frequent Deficiencies Found During FDA Inspections: Inadequate and Incorrect Records – 14 (25%) Failure to Adhere to Protocol – 10 (18%) Failure to Report Adverse Reactions – 3 (5%) Inadequate Drug Accountability – 3 (5%)

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 16 “Equivalent” Results of Personal Data RussiaUkraine NAI184 VAI634 OAI20 Total838

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 17 Audits in Russia and the Ukraine (Personal Data) Most Frequent “Equivalent” Deficiencies Found During the Audits (Personal Data): Inadequate and Incorrect Records – 35 (38%) Failure to Adhere to Protocol – 24 (26%) Failure to Report Adverse Reactions – 15 (16%) Inadequate Drug Accountability – 15 (16%)

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 18 Compliance Issues in Russia and the Ukraine Experience Level of Investigators: Quite a few Investigators are Still Inexperienced in Conducting Clinical Trials Studies (mainly Phase IV) Conducted by Local Pharmaceutical Companies are Still far from ICH GCP Standards National Authorities have only Started Continuous Inspections of Clinical Sites

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 19 Compliance Issues in Russia and the Ukraine Resolutions for Experience Level of Investigators: Monitors Experienced in Local and ICH GCP Requirements Intensive Investigators’ Training Sufficient Time for Site Management Audits of New Investigators

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 20 Compliance Issues in Russia and the Ukraine High Patient’s Recruitment Rate: High Ratio Patient per Site Higher Ratio active/ non-active Sites than in the West High Number of Patients are Enrolled within a Very Short Period of TimeResolutions: Increased Number of Monitors More Intense Monitoring Frequency

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 21 Compliance Issues in Russia and the Ukraine Cultural Features: Cultural Differences in Perception of Health, Symptoms, and PainResolution: Special Attention to the Registration of Adverse Events during Site Monitoring and Site Audits

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 22 Compliance Issues in Russia and the Ukraine Source Data: Very Detailed after Patient’s Enrollment Less Detailed with Regard to Patient’s Previous Medical HistoryResolutions: Intensive Site Monitoring Agreement on Source Documents Medical Background of Monitors/ Auditors

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 23 Compliance Issues in Russia and the Ukraine Language: English Skills of Investigators Translation of Study Documents MiscommunicationResolution: Monitors and Auditors with Knowledge of Local Language and English

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 24 Compliance Issues in Russia and the Ukraine Other Issues that can Influence Compliance: Less Efficient Logistics/ Transportation Limited Communication Infrastructure Lack of Standards in Local Laboratories Complicated Regulatory Process

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 25 Compliance Issues in Russia and the Ukraine Resolution - Other Issues: Local Drug Depot Experienced Courier Service Provision of Study Equipment to Sites Establishment of High-Speed Internet for Efficient Communication and EDC Continuous Monitoring on Regulatory Process

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 26 Recommendations Use Professionals with Local Expertise Conduct Intensive Site Monitoring and Site Management Monitors and Auditors – Medically Qualified and Trained to International Standards with Knowledge of Local Language

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 27 GCP QA for Russia and the Ukraine Thank you!

September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 28 Contact Information Dmitry V. Vorobiev, MD, PhD, MRQA Tel : Fax: Mob: